Recent Updates
Recently added Catalysts
HIMS Negative Sentiment

Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately

Key Takeaway: Wolf Haldenstein has filed a class action lawsuit against Hims & Hers Health, Inc. on behalf of investors who suffered losses between August 4, 2025, and July 29, 2026. The lawsuit claims that the company made false statements and failed to disclose critical information regarding its practices. Following the lawsuit, Hims & Hers' stock price fell significantly.

Market Sentiment Analysis

CONCERNS & RISKS

  • Hims & Hers faced a class action lawsuit for misleading investors.
  • The FTC alleges Hims & Hers failed to disclose immediate charges for prescriptions.
  • Stock price dropped 14.73% following negative news.

Full Press Release Details

NEW YORK , Sept. 15, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS ) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 22025,and July 29, 2026 (the "Class Period").
Investors who purchased Hims & Hers shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for November 2, 2026.
PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION
The filed complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failing to disclose material adverse facts to investors, including that
On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.
Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
There is no cost or obligation to speak with an attorney.
Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
* Firm Website: * Wolf Haldenstein Adler Freeman & Herz LLP
21 % more press release views with Request a Demo × Modal title Also from this source Shareholders who lost money in shares of acquired Papa John's International, Inc. (NASDAQ: PZZA) should contact Wolf Haldenstein Immediately Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a class action ...
Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a class action ...

Frequently Asked Questions

What is the class action lawsuit against Hims & Hers about?

The lawsuit claims Hims & Hers made false statements and failed to disclose important information to investors.

What allegations did the FTC make against Hims & Hers?

The FTC alleges Hims & Hers misled consumers about prescription charges and subscription cancellations.

When is the lead-plaintiff deadline for the lawsuit?

The lead-plaintiff deadline is set for November 2, 2026.

How much did Hims & Hers stock drop after the news?

Hims & Hers stock fell by $4.32 per share, or 14.73%, closing at $25.00.

Who is representing the investors in the lawsuit?

The law firm Wolf Haldenstein is representing the investors in the class action lawsuit.

Last updated: Sep 15, 2026